Marker Therapeutics, Inc. — Director's Dealing 2018

Oct 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2018-10-17

Reporting Person: Eansor Norman David (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-17	Non-Employee Director Stock Option (Right to Buy)	$8.34	A	12500	Acquired		Common Stock (12500)	Direct

Footnotes

F1: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018. These shares vest in monthly installments over a two year period. The option exercise price is the closing price on the date of the grant, October 17, 2018.